Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.

Bruserud Ø, Reikvam H, Fredly H, Skavland J, Hagen KM, van Hoang TT, Brenner AK, Kadi A, Astori A, Gjertsen BT, Pendino F.

Oncotarget. 2015 Feb 20;6(5):2794-811.

2.

CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.

Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud Ø.

Oncotarget. 2013 Sep;4(9):1438-48.

3.

Activation of both protein kinase A (PKA) type I and PKA type II isozymes is required for retinoid-induced maturation of acute promyelocytic leukemia cells.

Nguyen E, Gausdal G, Varennes J, Pendino F, Lanotte M, Døskeland SO, Ségal-Bendirdjian E.

Mol Pharmacol. 2013 May;83(5):1057-65. doi: 10.1124/mol.112.081034. Epub 2013 Mar 1.

4.

Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis.

Gausdal G, Wergeland A, Skavland J, Nguyen E, Pendino F, Rouhee N, McCormack E, Herfindal L, Kleppe R, Havemann U, Schwede F, Bruserud O, Gjertsen BT, Lanotte M, Ségal-Bendirdjian E, Døskeland SO.

Cell Death Dis. 2013 Feb 28;4:e516. doi: 10.1038/cddis.2013.39.

5.

Loss of the malignant phenotype of human neuroblastoma cells by a catalytically inactive dominant-negative hTERT mutant.

Samy M, Gattolliat CH, Pendino F, Hillion J, Nguyen E, Bombard S, Douc-Rasy S, Bénard J, Ségal-Bendirdjian E.

Mol Cancer Ther. 2012 Nov;11(11):2384-93. doi: 10.1158/1535-7163.MCT-12-0281. Epub 2012 Aug 28.

6.

Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors.

Pronier E, Almire C, Mokrani H, Vasanthakumar A, Simon A, da Costa Reis Monte Mor B, Massé A, Le Couédic JP, Pendino F, Carbonne B, Larghero J, Ravanat JL, Casadevall N, Bernard OA, Droin N, Solary E, Godley LA, Vainchenker W, Plo I, Delhommeau F.

Blood. 2011 Sep 1;118(9):2551-5. doi: 10.1182/blood-2010-12-324707. Epub 2011 Jul 6.

7.

hTERT promotes imatinib resistance in chronic myeloid leukemia cells: therapeutic implications.

Deville L, Hillion J, Pendino F, Samy M, Nguyen E, Ségal-Bendirdjian E.

Mol Cancer Ther. 2011 May;10(5):711-9. doi: 10.1158/1535-7163.MCT-10-0979. Epub 2011 Mar 1.

8.

RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer.

Knappskog S, Myklebust LM, Busch C, Aloysius T, Varhaug JE, Lønning PE, Lillehaug JR, Pendino F.

Ann Oncol. 2011 Oct;22(10):2208-15. doi: 10.1093/annonc/mdq737. Epub 2011 Feb 16.

9.

Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis.

Pendino F, Nguyen E, Jonassen I, Dysvik B, Azouz A, Lanotte M, Ségal-Bendirdjian E, Lillehaug JR.

Blood. 2009 Apr 2;113(14):3172-81. doi: 10.1182/blood-2008-07-170035. Epub 2009 Jan 30.

10.

LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro.

Huang TS, Myklebust LM, Kjarland E, Gjertsen BT, Pendino F, Bruserud Ø, Døskeland SO, Lillehaug JR.

Mol Cancer. 2007 Apr 23;6:31.

11.

Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths.

Wu YL, Dudognon C, Nguyen E, Hillion J, Pendino F, Tarkanyi I, Aradi J, Lanotte M, Tong JH, Chen GQ, Ségal-Bendirdjian E.

J Cell Sci. 2006 Jul 1;119(Pt 13):2797-806. Epub 2006 Jun 13.

12.

Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase.

Arnesen T, Betts MJ, Pendino F, Liberles DA, Anderson D, Caro J, Kong X, Varhaug JE, Lillehaug JR.

BMC Biochem. 2006 Apr 25;7:13.

13.

Telomeres and telomerase: Pharmacological targets for new anticancer strategies?

Pendino F, Tarkanyi I, Dudognon C, Hillion J, Lanotte M, Aradi J, Ségal-Bendirdjian E.

Curr Cancer Drug Targets. 2006 Mar;6(2):147-80. Review.

PMID:
16529544
14.

Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex.

Arnesen T, Gromyko D, Pendino F, Ryningen A, Varhaug JE, Lillehaug JR.

Oncogene. 2006 Jul 20;25(31):4350-60. Epub 2006 Mar 6.

PMID:
16518407
15.

Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL.

Pendino F, Hillion J, Dudognon C, Delaunay J, Mourah S, Podgorniak MP, Lafon I, Chomienne C, Lanotte M, Dombret H, Rousselot P, Ségal-Bendirdjian E.

Leukemia. 2006 Apr;20(4):599-603.

PMID:
16482212
16.

Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death.

Tarkanyi I, Dudognon C, Hillion J, Pendino F, Lanotte M, Aradi J, Ségal-Bendirdjian E.

Leukemia. 2005 Oct;19(10):1806-11.

PMID:
16107885
17.

Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance.

Dudognon C, Pendino F, Hillion J, Saumet A, Lanotte M, Ségal-Bendirdjian E.

Oncogene. 2004 Sep 30;23(45):7469-74.

PMID:
15326479
18.

Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death.

Pendino F, Dudognon C, Delhommeau F, Sahraoui T, Flexor M, Bennaceur-Griscelli A, Lanotte M, Ségal-Bendirdjian E.

Oncogene. 2003 Dec 11;22(57):9142-50.

PMID:
14668795
19.
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk